Janux Therapeutics(JANX) - 2025 Q2 - Quarterly Results

Janux Therapeutics Reports Second Quarter 2025 Financial Results and Business Highlights SAN DIEGO, August 7, 2025 – Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technologies to its Tumor Activated T Cell Engager (TRACTr), Tumor Activated Immunomodulator (TRACIr), and Adaptive Immune Response Modulator (ARM) platforms, today reported financial results for the second quarter ended J ...